Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.6902
-0.0638 (-8.46%)
At close: Aug 25, 2025, 4:00 PM
0.6979
+0.0077 (1.12%)
After-hours: Aug 25, 2025, 4:01 PM EDT
Palisade Bio Employees
Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,480,625
Market Cap
6.29M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8 | -1 | -11.11% |
Dec 31, 2023 | 9 | -3 | -25.00% |
Dec 31, 2022 | 12 | -1 | -7.69% |
Dec 31, 2021 | 13 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PALI News
- 7 hours ago - Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 - GlobeNewsWire
- 18 days ago - Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 - GlobeNewsWire
- 25 days ago - Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China - GlobeNewsWire
- 4 weeks ago - Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million - GlobeNewsWire
- 4 weeks ago - Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 6 weeks ago - Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors - GlobeNewsWire
- 3 months ago - Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis - GlobeNewsWire
- 3 months ago - Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases - GlobeNewsWire